Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Inclusion Criteria: * Male and female subjects who: * received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225 * understand the nature of the study, agree to its provisions and provide written informed consent * are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial) * have a negative pregnancy test result at the first medical examination (if female and capable of bearing children) * agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children) * agree to keep a Subject Diary Exclusion Criteria: Subjects who: * have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225 * have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis) * have had an allergic reaction to one of the components of the vaccine since participation in Study 225 * suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions * have a known or suspected problem with drug or alcohol abuse (\>4 liters wine/week or equivalent doses of other alcoholic beverages) * have donated blood or plasma within 30 days of study entry * have received a blood transfusion or immunoglobulins within 30 days of study entry * are known to be HIV positive (an HIV test is not required specifically for this study) * are simultaneously participating in another clinical trial including administration of an investigational product * have participated in any other clinical study within 6 weeks prior to study start * have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies) * For female subjects: pregnancy or lactation